543 related articles for article (PubMed ID: 10569939)
21. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
22. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
23. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin.
Hautefaye P; Cimetière B; Pierré A; Léonce S; Hickman J; Laine W; Bailly C; Lavielle G
Bioorg Med Chem Lett; 2003 Aug; 13(16):2731-5. PubMed ID: 12873503
[TBL] [Abstract][Full Text] [Related]
25. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors.
Liu W; Zhu L; Guo W; Zhuang C; Zhang Y; Sheng C; Cheng P; Yao J; Wang W; Dong G; Wang S; Miao Z; Zhang W
Eur J Med Chem; 2011 Jun; 46(6):2408-14. PubMed ID: 21463912
[TBL] [Abstract][Full Text] [Related]
27. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y
Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334
[TBL] [Abstract][Full Text] [Related]
28. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
Teicher BA
Biochem Pharmacol; 2008 Mar; 75(6):1262-71. PubMed ID: 18061144
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of 9-benzylideneamino derivatives of homocamptothecin as potent inhibitors of DNA topoisomerase I.
Guo W; Miao Z; Sheng C; Yao J; Feng H; Zhang W; Zhu L; Liu W; Cheng P; Zhang J; Che X; Wang W; Luo C; Xu Y
Eur J Med Chem; 2010 Jun; 45(6):2223-8. PubMed ID: 20202723
[TBL] [Abstract][Full Text] [Related]
30. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues.
Kim DK; Ryu DH; Lee JY; Lee N; Kim YW; Kim JS; Chang K; Im GJ; Kim TK; Choi WS
J Med Chem; 2001 May; 44(10):1594-602. PubMed ID: 11334569
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells.
Lansiaux A; Facompré M; Wattez N; Hildebrand MP; Bal C; Demarquay D; Lavergne O; Bigg DC; Bailly C
Mol Pharmacol; 2001 Sep; 60(3):450-61. PubMed ID: 11502875
[TBL] [Abstract][Full Text] [Related]
33. Trifluoromethyl-promoted homocamptothecins: synthesis and biological activity.
Zhu L; Miao Z; Sheng C; Guo W; Yao J; Liu W; Che X; Wang W; Cheng P; Zhang W
Eur J Med Chem; 2010 Jul; 45(7):2726-32. PubMed ID: 20304538
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Ling YH; Andersson BS; Nelson JA
Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues.
Sugimori M; Ejima A; Ohsuki S; Uoto K; Mitsui I; Kawato Y; Hirota Y; Sato K; Terasawa H
J Med Chem; 1998 Jun; 41(13):2308-18. PubMed ID: 9632364
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationship study of 16 a-thiocamptothecins: an integrated in vitro and in silico approach.
Samorì C; Beretta GL; Varchi G; Guerrini A; Di Micco S; Basili S; Bifulco G; Riccio R; Moro S; Bombardelli E; Zunino F; Fontana G
ChemMedChem; 2010 Dec; 5(12):2006-15. PubMed ID: 21069656
[TBL] [Abstract][Full Text] [Related]
37. New homocamptothecins: synthesis, antitumor activity, and molecular modeling.
Miao Z; Sheng C; Zhang W; Ji H; Zhang J; Shao L; You L; Zhang M; Yao J; Che X
Bioorg Med Chem; 2008 Feb; 16(3):1493-510. PubMed ID: 18207748
[TBL] [Abstract][Full Text] [Related]
38. Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
Gamage SA; Spicer JA; Finlay GJ; Stewart AJ; Charlton P; Baguley BC; Denny WA
J Med Chem; 2001 Apr; 44(9):1407-15. PubMed ID: 11311063
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacology of camptothecin and its derivatives].
Rivory LP; Robert J
Bull Cancer; 1995 Apr; 82(4):265-85. PubMed ID: 10846537
[TBL] [Abstract][Full Text] [Related]
40. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.
Liao Z; Robey RW; Guirouilh-Barbat J; To KK; Polgar O; Bates SE; Pommier Y
Mol Pharmacol; 2008 Feb; 73(2):490-7. PubMed ID: 17984197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
